Journal of the Korea Academia-Industrial cooperation Society (한국산학기술학회논문지)

The Korea Academia-Industrial cooperation Society (한국산학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Development of a novel combination tablet containing silodosin and solifenacin succinate for the treatment of urination disorder

배뇨 장애 치료를 위한 실로도신과 솔리페나신 숙신산염 함유한 새로운 복합 정제 개발

  • Choi, Hyung-Joo (Department of Pharmaceutical Engineering, Gyeongnam National University of Science and Technology) ;
  • Lee, Jeong-Gyun (Department of Pharmaceutical Engineering, Gyeongnam National University of Science and Technology) ;
  • Kim, Kyeong Soo (Department of Pharmaceutical Engineering, Gyeongnam National University of Science and Technology)
  • 최형주 (경남과학기술대학교 제약공학과) ;
  • 이정균 (경남과학기술대학교 제약공학과) ;
  • 김경수 (경남과학기술대학교 제약공학과)
  • Received : 2020.12.11
  • Accepted : 2021.03.05
  • Published : 2021.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study was undertaken to develop a new combination tablet containing silodosin and solifenacin succinate for treating urination disorders, for which a simultaneous analytical method of silodosin and solifenacin succinate was established. The aqueous solubility of silodosin and solifenacin succinate was determined to be higher than 1 mg/ml in various buffers, and dissolution of the silodosin and solifenacin succinate commercial products was accomplished within 30 minutes. The drug-excipients compatibility test was subsequently evaluated using differential scanning calorimetry. Excipients without compatibility were selected, and various combination formulations were prepared applying the wet granulation method. Of these, the formulation comprising silodosin, solifenacin succinate, lactose hydrate, MCC PH101, sodium lauryl sulfate (SLS), Povidone K30, crospovidone and magnesium stearate, having a weight ratio of 8/10/56/112/2/6/6/2, respectively, showed equivalence comparative to the dissolution achieved with the commercial products of silodosin (Thrupas tab) and solifenacin succinate (Vesicare tab). Thus, we propose that compared to the currently available commercial products, this novel combination tablet containing silodosin and solifenacin succinate is an effective alternative for the treatment of urination disorders.

본 연구의 목적은 배뇨장애 치료를 위한 실로도신과 솔리페나신 숙신산염을 함유한 새로운 복합 정제를 개발하는 것이다. 이러한 목표를 달성하기 위하여 실로도신과 솔리페나신 숙신산염의 동시 정량법을 확립하였다. 두 약물은 다양한 완충액에서 1 mg/ml 이상의 수용해도 값을 나타내었으며, 실로도신과 솔리페나신 숙신산염이 함유된 시판제품의 용출은 다양한 용출조건에서 30분 이내에 완료되었다. 시차 주사 열량계를 사용하여 부형제와 약물 간 상호 반응성을 확인하여 선정된, 약물과 반응성이 없는 부형제를 사용하여 습식 과립화 방법을 사용하여 결합제와 붕해제의 사용에 따른 다양한 처방을 제조한 후 용출시험을 진행하였다. 제조한 정제의 처방 중 실로도신, 솔리페나신 숙신산염, 유당, 미결정셀룰로오스 PH101, 소듐라우릴설페이트, 포비돈 K-30, 크로스포비돈 및 스테아린산마그네슘이 8/10/56/112/2/6/6/2(w/w)의 비율로 제조된 정제는 트루패스정(실로도신 시판 제품) 및 베시케어정(솔리페나신 숙신산염 시판 제품)과의 비교용출 시험시 동등성을 나타내는 것을 확인하였다. 따라서, 본 연구를 통해 얻어진 복합 정제는 각 약물의 시판 제품과 동등한 생체이용률을 나타낼 수 있을 것으로 판단되며, 향후 배뇨 장애 치료에 복약순응도가 우수한 의약품으로 활용될 수 있을 것으로 사료된다.

Keywords

References

  1. P. Abrams, C. Chapple, S. Khoury, C. Roehrborn, J. Rosette et al., "Evaluation and treatment of lower urinary tract symptoms in older men", The Journal of Urology, Vol.181, pp.1779-1787, 2009. DOI: https://doi.org/10.1016/j.juro.2008.11.127
  2. A. S. Salinas-Sanchez, I. Hernandez-Millan, J. G. Lorenzo-Romero, M. Segura-Martin, C. Fernandez-Olano et al., "Quality of lifeof patients on the waiting list for benign prostatic hyperplasia surgery", Quality of Life Research, Vol.10, pp.543-553, 2001. DOI: https://doi.org/10.1023/A:1013004602682
  3. M. Yoshida, J. Kudoh, Y. Homma, K. Kawabe. "Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia", Clinical Intervention in Aging, Vol.6, pp.161-172, 2011. DOI: https://doi.org/10.2147/CIA.S13803
  4. S. J. Oh, "Review of the Anticholinergics for the Treatment of Overactive Bladder: 2009 Update", International Neurourology Journal, Vol.13, pp.7-22, 2009. DOI: https://doi.org/10.5213/jkcs.2009.13.1.7
  5. K. Lee, M. Choo, D. Kim, J. Kim, H. Kim et al., "Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: A prosptective, randomized, controlled multicenter study", The Journal of Urology, Vol.174, pp.1334-1338, 2005. DOI:　https://doi.org/10.1097/01.ju.0000173630.94559.fd
  6. C. Cheong, J. C. Barner, K. A. Lawson, M. T. Johnsrud, "Patient Adherence and Reimbursement Amount for Antidiabetic Fixed-Dose Combination Products Compared with Dual Therapy Among Texas Medicaid Recipients", Clinical Therapeutics. Vol.30, pp.1893-1907, 2008. DOI: https://doi.org/10.1016/j.clinthera.2008.10.003
  7. J. Kim, K. Kim, D. Kim, S. Jin, D. Kim et al., "Effect of HM30181 mesylatesalt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor", International Journal of Pharmaceutics, Vol.506, pp.93-103, 2016. DOI: https://doi.org/10.1016/j.ijpharm.2016.04.034
  8. Y. Sohn, A. Lee, "Compatibility Study Using Differential Scanning Calorimetry", Journal of Pharmaceutical Investigation, Vol.29, pp.117-126, 1999.
  9. H. Moon, A. Yousaf, K. Cho, C. Yong, J. Kim et al., "Evaluation of stability and simultaneous determination of fimasartan and amlodipine by a HPLC method in combination tablets", Asian Journal of Pharmaceutical Sciences, Vol.9, pp.123-128, 2014. DOI: https://doi.org/10.1016/j.ajps.2014.04.002
  10. L. Martinez, E. Uribarri, A. Laguna, "Characterization and Compatibility Studies between Policosanol, a New Hypocholesterolemic Drug, and Tablet Excipients Using Differential Scanning Calorimetry (DSC)", Archiv der Pharmazie, Vol.332, pp.439-441, 1999. DOI: https://doi.org/10.1002/(SICI)1521-4184(199912)332:12<439::AID-ARDP439>3.0.CO;2-5
  11. M. Kim, "Compatibility Study of Excipients for Pravastatin Tablet", Journal of Life Science, Vol.28, pp.472-477, 2018. DOI: https://doi.org/10.5352/JLS.2018.28.4.472
  12. P. Tian, F. Yang, L. P. Yu, M. M. Lin, W. Lin et al., "Applications of excipients in ther field of 3D printed pharmaceuticals:,. Drug Development and Industrial Pharmacy, Veol.45, pp.905-913, 2019. DOI: https://doi.org/10.1080/03639045.2019.1576723
  13. C. Kim, S. Lee, K. Kim, "Development of a novel dapagliflozin orally disintegrating tablets", Yakhak Hoeji, Vol.64, pp.334-342, 2020. DOI: https://doi.org/10.17480/psk.2020.64.4.334
  14. K. Cho, Y. Choi, J. Kang, H. Choi, C. Y. J. Park et al., "Development of a novel combination table containing trimebutine maleate and mosaprid citrate for the treatment of functional dyspepsia", International Journal of Pharmaceutics, Vol.400, pp.145-152, 2010. DOI: https://doi.org/10.1016/j.ijpharm.2010.08.047
  15. H. T. Lim, P. Balakrishnan, D. Oh, K. Joe, Y. Kim et al., "Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: Physicochemical characterization and pharmacokenetics in beagle dogs", International Journal of Pharmaceutics, Vol.397, pp.225-230, 2010. DOI: https://doi.org/10.1016/j.ijpharm.2010.07.013
  16. J. H. Cho, J. C. Kim, H. S. Kim, D. S. Kim, K. S. Kim et al., "Novel dabigatran etexilate hemisuccinate-loaded polycp: Physicochemical characterization and in vivo evaluation in beagle dogs", International Journal of Pharmaceutics, Vol.525, pp.60-70, 2017. DOI: http://dx.doi.org/10.1016/j.ijpharm.2017.04.028